Based on the key measurements obtained from Inozyme Pharma's financial statements, Inozyme Pharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Inozyme Pharma's Accumulated Other Comprehensive Income is fairly stable compared to the past year. Capital Stock is likely to rise to 6,300 in 2024, whereas Total Assets are likely to drop slightly above 132.8 M in 2024. Key indicators impacting Inozyme Pharma's financial strength include:
The financial analysis of Inozyme Pharma is a critical element in measuring its lifeblood. Investors should not minimize Inozyme Pharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(74.73 Million)
Inozyme
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Common Stock
Property Plant Equipment
Property Plant And Equipment Gross
Short Long Term Debt Total
Retained Earnings Total Equity
Capital Lease Obligations
Inventory
Non Current Liabilities Other
Short Term Debt
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Cost Of Revenue
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Inozyme Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Inozyme Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Inozyme Pharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Inozyme Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inozyme Pharma. Check Inozyme Pharma's Beneish M Score to see the likelihood of Inozyme Pharma's management manipulating its earnings.
Inozyme Pharma Stock Summary
Inozyme Pharma competes with Day One, X4 Pharmaceuticals, Acumen Pharmaceuticals, Mereo BioPharma, and Terns Pharmaceuticals. Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Inozyme Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Inozyme Pharma. It measures of how well Inozyme is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Inozyme Pharma brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Inozyme had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Inozyme Pharma has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Inozyme Pharma's current stock value. Our valuation model uses many indicators to compare Inozyme Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inozyme Pharma competition to find correlations between indicators driving Inozyme Pharma's intrinsic value. More Info.
Inozyme Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Inozyme Pharma's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inozyme Pharma's earnings, one of the primary drivers of an investment's value.
Inozyme Pharma Systematic Risk
Inozyme Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Inozyme Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Inozyme Pharma correlated with the market. If Beta is less than 0 Inozyme Pharma generally moves in the opposite direction as compared to the market. If Inozyme Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Inozyme Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Inozyme Pharma is generally in the same direction as the market. If Beta > 1 Inozyme Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Inozyme Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inozyme Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Inozyme Pharma growth as a starting point in their analysis.
Inozyme Pharma November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Inozyme Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Inozyme Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Inozyme Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Inozyme Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inozyme Pharma's daily price indicators and compare them against related drivers.
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.